The timing between the diagnosis and the end of the last treatment in the cancer continuum in patients with lung cancer by TNM stages; and the impact of delays in the final survival of the patients, in PLCO, In the period available in the data set.
Principal Investigator
Name
Percy Guzman
Degrees
MD, MSc
Institution
NCI
Position Title
NCI Fellow
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-1036
Initial CDAS Request Approval
Sep 6, 2022
Title
The timing between the diagnosis and the end of the last treatment in the cancer continuum in patients with lung cancer by TNM stages; and the impact of delays in the final survival of the patients, in PLCO, In the period available in the data set.
Summary
Lung cancer is in the top five for incidence and mortality. The beginning of treatments after cancer diagnosis has not been clearly established, only arbitrary values are used so that the patient receives his treatment after his treatment. The project seeks to see if there is a relationship between the delays in receiving the treatment and the final survival of the patient, taking as a reference point the time of tumor duplication.
Aims
o Observe the general characteristics in patients with lung cancer.
o Describe the time of each treatment process, during and after diagnosis of lung cancer.
o Identify the factors that intervene throughout the continuum of cancer and produce delays in the screening, diagnosis, and treatment pathway.
o Analyze the survival of lung cancer patients by TNM stages.
o Describe at what point (number of weeks after diagnosis) we do or do not observe delays in the lung cancer continuum.
Collaborators
Michael Halpern